IL2 and cancer: Hence, an earlier review highlighted that RBAC could be an adjuvant to cancer treatment, with RBAC working synergistically with IL-2, NKC, and chemotherapeutic agents to overcome the dysregulated apoptosis associated with excess oxidative stress in malignancy [21].